Join BioInvent for a virtual key opinion leader (KOL) event featuring Dmitriy Zamarin MD, PhD (Tisch Cancer Center, Icahn School of Medicine at Mount Sinai), who will join company management to discuss the unmet need and current treatment landscape for ovarian cancer.

The event will provide an overview of BI-1808, a first-in-class drug candidate which has shown clinical proof-of-concept (single agent as well as in combination with pembrolizumab) in clinical Phase 2 development for the treatment of ovarian cancer. The interim data from 21 evaluable patients who received BI-1808 plus pembrolizumab showed three times the overall response rate (ORR) of pembrolizumab alone in heavily pretreated ovarian cancer patients. Management will also discuss the competitive differentiation as well as upcoming data milestones. This event is the first in a two-part KOL series. A second event taking place on June 11th will focus on BI-1206 and BI-1808 for the treatment of non-Hodgkin’s lymphoma and cutaneous T-cell lymphoma, respectively.

A live question and answer session will follow the formal presentations.